AI can revolutionize medicine by enhancing drug development efficiency, accuracy and cost-effectiveness. Cure and The New York Academy of Sciences with Nicholas Dirks bring you a very special episode of Tuesday talks with a panel of experts including George Church of Harvard University, Maria Luisa Pineda, PhD. of Envisagenics Grant W Mitchell, MD, MBA, of Every Cure and Thomas Fuchs of Icahn School of Medicine at Mount Sinai who will discuss AI's transformative role in bringing patients more effective treatments faster. #aiforgood #wewillcure
Cure.’s Post
More Relevant Posts
-
AI can revolutionize medicine by enhancing drug development efficiency, accuracy and cost-effectiveness. Cure and The New York Academy of Sciences with Nicholas Dirks bring you a very special episode of Tuesday Talks with Seema Kumar with a panel of experts including George Church of Harvard Medical School, Maria Luisa Pineda, PhD. of Envisagenics, Grant W Mitchell, MD, MBA, of Every Cure and Thomas Fuchs of Icahn School of Medicine at Mount Sinai who will discuss AI's transformative role in bringing patients more effective treatments faster. #aiforgood #wewillcure
The Science & Business of AI-Driven Drug Discovery
www.linkedin.com
To view or add a comment, sign in
-
Stanford Chair of Genetics: "Modern medicine is broken beyond repair" With healthcare systems creaking under the weight of chronic under-investment and record-high waiting lists, Prof Michael Snyder is calling for a healthcare revolution that throws out generic care, prescriptions and treatment in favour of a truly personalised approach that capitalises on the latest genetic, tech and medical breakthroughs. But can his vision ever become a reality in the face of fervent resistance from Big Pharma and other powerful vested interests with bottomless pockets? Unfiltered https://lnkd.in/eFCagBu9
To view or add a comment, sign in
-
Explore how crowdsourcing can revolutionize translational medicine and medical innovation. Learn about the invaluable role of citizen science in enhancing clinical research, particularly in rare disease studies, and how AI is amplifying these efforts. Discover why involving patients and caregivers can accelerate scientific discoveries and empower individuals in their health journey.
To view or add a comment, sign in
-
Two burning questions for the AI curious among us: 1) When was artificial intelligence first used in medicine? 2) What do we expect to be the first medicine to hit the market thanks to AI? Here are your answers, you can freely quote me when you're showing off your state-of-the-art knowledge on AI and medicine... 😉 1. It was back in 1973 when the "Stanford University Medical Experimental–Artificial Intelligence in Medicine", a time-shared computer system, was created, combining the know-how of many clinical and biomedical researchers from several institutions. 2. Insilico Medicine (Hong Kong, New York) — used AI to develop an experimental drug for the incurable lung disease idiopathic pulmonary fibrosis. The treatment is in mid-stage trials in the US and China with some results expected early 2025. Don't forget for all your business development and recruitment needs, we're right there for you: [email protected]
To view or add a comment, sign in
-
-
AI Product Owner - Wendy’s | Driving Innovation in Fast-Food Technology | Customer Experience Advocate 🍔 🤖
🤯 😮 💊 What if you could explore in detail every cell of the body, in any phase or situation you could imagine? Steve Quake and the team at Chan Zuckerberg Initiative are trying to do just that. In this video he discusses the groundbreaking use of AI in healthcare, specifically in early cancer detection and understanding complex cellular systems. Their work includes creating comprehensive cell atlases and a vast AI computing cluster, aiding in cellular therapy and disease prevention. This initiative, merging AI with life sciences, presents an incredible, transformative future for medicine. Really incredible stuff! (https://lnkd.in/eN7hNBsk) #HealthcareInnovation #ArtificialIntelligence #MedicalTechnology #CancerResearch #CellularBiology #ChanZuckerbergInitiative #AIinMedicine #DigitalHealth #ScienceAdvancement #futureofhealthcare
Stanford professor on the future of life-saving medicine | Steve Quake
https://www.youtube.com/
To view or add a comment, sign in
-
Looking forward to Desiree Abdurrachim's talk on Multi-modal AI Digital Pathology to Accelerate MASH Drug Discovery! Have you secured your seat for the 8th Digital Pathology & AI Congress Asia 2024 yet?
We are thrilled to introduce Desiree Abdurrachim, our Speaker at the upcoming 8th Digital Pathology & Ai Congress Asia, taking place in Singapore. Desiree Abdurrachim is Principal Scientist from MSD Singapore. She brings a wealth of knowledge and insights that are sure to inspire and inform our attendees. 📅 Save the Date: 10th – 11th September 2024 📍 Location: NTU Lee Kong Chian School of Medicine 🔗 Learn More and Register: https://lnkd.in/dX-JR6dU Don't miss this opportunity to learn from one of the leading quality experts in the industry. Register now and join us for an enlightening and engaging experience!
To view or add a comment, sign in
-
-
Let’s talk about speech, baby 💬 New publication alert! 👇 We summarised current evidence of digitally collected speech biomarkers in #motorneurondisease #amyotrophiclateralsclerosis Led by superstar medical student Molly Bowden, our team systematically reviewed 40 studies using digital devices to assess speech. Key takeaways: 1️⃣ Changes in speech show early potential in differentiating people with MND and healthy controls 2️⃣ Speech is a promising potential avenue for early detection of MND 3️⃣ Digital data collection enables assessments at home and can reduce the burden of travel Whilst further research is definitely needed, reviews like these provide essential backgrounds to what has (and hasn’t!) worked so far. Check out the full paper at NPJ Digital Medicine: link in comments 👋 ______________________________________________________ A great way to round off a busy year and looking forward to 2024... ...but for now I’m off for two weeks of hibernation with my pups!
To view or add a comment, sign in
-
-
Regulatory Director | Regulatory endorsements of drug development tools | Cross-functional collaborations | Diverse disease portfolio | Lead people; Manage projects | Mentor STEM students
What is the future of #artificialintelligence? Here is a great step forward for #innovationinhealthcare and the potentials of using #AI to derive #clinicaloutcomeassessments for #regulatorydecisions. Keeping my eyes on this one 👀.
FDA's Innovative Science and Technology Approaches for New Drugs (ISTAND) Pilot Program has accepted a submission of the first artificial intelligence-based and digital health technology for neuroscience: https://lnkd.in/erifXNaR
To view or add a comment, sign in
-
-
The accepted LOI submission is for an automated depression and anxiety severity measurement tool utilizing multiple behavioral and physiological indices of depression in a machine learning (ML) model to derive clinician-reported outcomes for depression and anxiety based on the Hamilton Depression Rating Scale (HAM-D) and Hamilton Anxiety Rating Scale (HAM-A) scores.
FDA's Innovative Science and Technology Approaches for New Drugs (ISTAND) Pilot Program has accepted a submission of the first artificial intelligence-based and digital health technology for neuroscience: https://lnkd.in/erifXNaR
To view or add a comment, sign in
-
-
🎥 We caught up with PathAI CEO, Andrew Beck, VP of Product Ben Glass, and Sr. Translational Scientist Lara P. Murray, PhD to hear their perspective on the impact of our recent #NatureMedicine publication entitled “𝗔𝗜-𝗯𝗮𝘀𝗲𝗱 𝗮𝘂𝘁𝗼𝗺𝗮𝘁𝗶𝗼𝗻 𝗼𝗳 𝗲𝗻𝗿𝗼𝗹𝗹𝗺𝗲𝗻𝘁 𝗰𝗿𝗶𝘁𝗲𝗿𝗶𝗮 𝗮𝗻𝗱 𝗲𝗻𝗱𝗽𝗼𝗶𝗻𝘁 𝗮𝘀𝘀𝗲𝘀𝘀𝗺𝗲𝗻𝘁 𝗶𝗻 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝘁𝗿𝗶𝗮𝗹𝘀 𝗶𝗻 𝗹𝗶𝘃𝗲𝗿 𝗱𝗶𝘀𝗲𝗮𝘀𝗲𝘀” which details the development of our solution, AIM-MASH™. Hear more about the details behind developing AIM-MASH™ and using AI-powered #pathology to solve pressing problems in #healthtech, #translationalresearch, clinical trial #enrollment, and more. 📝 You can read the original article here: https://lnkd.in/gaiqqeUx Successful clinical trials in metabolic dysfunction-associated steatohepatitis (#MASH) rely on consistent histologic scoring, which has historically been variable. The developed AI-based measurement tool (AIM-MASH™) demonstrated reproducibility and alignment with expert pathologists, and has the potential to reduce inter-rater variability in MASH clinical trials. AIM-MASH additionally produces continuous scores for each of the MASH CRN (#ClinicalResearchNetwork) components to enable granular measurement of histologic changes. Read more about AIM-MASH, #pathology, and more in our latest paper and by visiting our website: https://lnkd.in/e5c4W8Xc AIM-MASH™ is for research use only. Not for use in diagnostic procedures. #Pathology #biotechnology #biotech #healthcare #machinelearning #MASH #LiverDisease #AI #clinicaltrials
To view or add a comment, sign in